{"name":"Ocuphire Pharma","slug":"ocuphire","ticker":"OCRX","exchange":"NASDAQ","domain":"ocuphire.com","description":"Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic disorders. The company's lead product candidates, PHX-1766 and PHX-3110, are being developed for the treatment of presbyopia and myopia, respectively. Ocuphire Pharma has a strong pipeline and is well-positioned to address the growing demand for ophthalmic treatments.","hq":"Farmington Hills, MI","founded":0,"employees":"","ceo":"Mina Sooch","sector":"Ophthalmology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":5476776,"netIncome":-49591000,"cash":50243000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"PHX-1766 patent cliff ($0.00 at risk)","drug":"PHX-1766","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"PHX-3110 patent cliff ($0.00 at risk)","drug":"PHX-3110","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Low dose pilocarpine","genericName":"Low dose pilocarpine","slug":"low-dose-pilocarpine","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"Phentolamine Opthalmic Solution 0.75%","genericName":"Phentolamine Opthalmic Solution 0.75%","slug":"phentolamine-opthalmic-solution-0-75","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Phentolamine Mesylate Ophthalmic Solution 1%","genericName":"Phentolamine Mesylate Ophthalmic Solution 1%","slug":"phentolamine-mesylate-ophthalmic-solution-1","indication":"Other","status":"phase_2"},{"name":"Phentolamine Ophthalmic Solution 0.75%","genericName":"Phentolamine Ophthalmic Solution 0.75%","slug":"phentolamine-ophthalmic-solution-0-75","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APX3330","genericName":"APX3330","slug":"apx3330","indication":"Treatment of diabetic retinopathy","status":"phase_2"}]}],"pipeline":[{"name":"APX3330","genericName":"APX3330","slug":"apx3330","phase":"phase_2","mechanism":"Inhibits the enzyme TGFBR2","indications":["Treatment of diabetic retinopathy"],"catalyst":""},{"name":"Low dose pilocarpine","genericName":"Low dose pilocarpine","slug":"low-dose-pilocarpine","phase":"phase_3","mechanism":"Low-dose pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase aqueous humor outflow and reduce intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Phentolamine Mesylate Ophthalmic Solution 1%","genericName":"Phentolamine Mesylate Ophthalmic Solution 1%","slug":"phentolamine-mesylate-ophthalmic-solution-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phentolamine Ophthalmic Solution 0.75%","genericName":"Phentolamine Ophthalmic Solution 0.75%","slug":"phentolamine-ophthalmic-solution-0-75","phase":"phase_3","mechanism":"Phentolamine is an alpha-adrenergic antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve visual function in patients with presbyopia.","indications":["Presbyopia (age-related loss of accommodation)"],"catalyst":""},{"name":"Phentolamine Opthalmic Solution 0.75%","genericName":"Phentolamine Opthalmic Solution 0.75%","slug":"phentolamine-opthalmic-solution-0-75","phase":"phase_3","mechanism":"Phentolamine is an alpha-adrenergic receptor antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve aqueous humor outflow.","indications":["Presbyopia (age-related loss of accommodation)","Intraocular pressure reduction in glaucoma or ocular hypertension (investigational)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Ocuphire Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ocuphire Pharma reported its financial results for the fourth quarter and full year 2023, highlighting a strong cash position and progress in its clinical pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Ocuphire Pharma Announces Collaboration with the University of California, Los Angeles (UCLA)","summary":"Ocuphire Pharma announced a collaboration with UCLA to develop novel treatments for ophthalmic disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"PHX-1766","drugSlug":"none","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"PHX-3110","drugSlug":"none","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Regeneron","Novartis"],"therapeuticFocus":["Presbyopia","Myopia"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":0,"period":"2013-12-31"},{"value":0,"period":"2013-12-31"},{"value":0,"period":"2012-12-31"},{"value":0,"period":"2011-12-31"},{"value":0,"period":"2010-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5476776,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49591000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":50243000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}